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Abstract
Background: Death receptors (DR) of the TNF family function as anti-tumor immune effector molecules. Tumor cells,
however, often exhibit DR-signaling resistance. Previous studies indicate that radiation can modify gene expression within
tumor cells and increase tumor cell sensitivity to immune attack. The aim of this study is to investigate the synergistic effect
of sub-lethal doses of ionizing radiation in sensitizing colorectal carcinoma cells to death receptor-mediated apoptosis.
Methodology/Principal Findings: The ability of radiation to modulate the expression of multiple death receptors (Fas/
CD95, TRAILR1/DR4, TRAILR2/DR5, TNF-R1 and LTbR) was examined in colorectal tumor cells. The functional significance of
sub-lethal doses of radiation in enhancing tumor cell susceptibility to DR-induced apoptosis was determined by in vitro
functional sensitivity assays. The longevity of these changes and the underlying molecular mechanism of irradiation in
sensitizing diverse colorectal carcinoma cells to death receptor-mediated apoptosis were also examined. We found that
radiation increased surface expression of Fas, DR4 and DR5 but not LTbR or TNF-R1 in these cells. Increased expression of
DRs was observed 2 days post-irradiation and remained elevated 7-days post irradiation. Sub-lethal tumor cell irradiation
alone exhibited minimal cell death, but effectively sensitized three of three colorectal carcinoma cells to both TRAIL and Fas-
induced apoptosis, but not LTbR-induced death. Furthermore, radiation-enhanced Fas and TRAIL-induced cell death lasted
as long as 5-days post-irradiation. Specific analysis of intracellular sensitizers to apoptosis indicated that while radiation did
reduce Bcl-XL and c-FLIP protein expression, this reduction did not correlate with the radiation-enhanced sensitivity to Fas
and/or TRAIL mediated apoptosis among the three cell types.
Conclusions/Significance: Irradiation of tumor cells can overcome Fas and TRAIL resistance that is long lasting. Overall,
results of these investigations suggest that non-lethal doses of radiation can be used to make human tumors more
amenable to attack by anti-tumor effector molecules and cells.
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Introduction
Ionizing radiation (IR) has been administered clinically for the
treatment of a wide range of human cancers for more than 100
years. Currently, it is the standard of care for many cancers,
including colorectal cancer [1–3]. As a definitive therapy,
radiation therapy (RT) has been used for the local control of
tumor growth. Used in this manner, RT fails to control
disseminated metastatic disease [4], which remains the primary
cause of mortality of colorectal cancer patients [5,6]. Moreover,
many tumors develop resistance to death induction by radiation.
To overcome this barrier research and clinical trials have
demonstrated that combining RT with other treatments is often
more effective than RT alone [7,8]. In this regard numerous
studies indicate that IR has immuno-stimulatory properties and
can enhance immune responses to tumor cells [9–16] and there is
a wide array of immunotherapy strategies under clinical
investigation in combination with RT [17]. The host immune
system functions to suppress tumor cell growth in a process called
tumor immunosurveillance [18] and important anti-tumor agents
under consideration include both immune cells and immune
effector molecules [19–23]. Many of these clinical investigations
utilize RT as an adjuvant to such novel, immune-based therapies
[13,24–26]. While some of these studies reported enhanced
immunological responses, none of the studies using RT as an
adjuvant to immune-based therapy have reported significant
reduction in tumor burden following therapy. Thus, better
defining the molecular details of enhanced immune modulation
by IR is critical to optimizing this strategy.
Death receptors of the tumor necrosis factor receptor (TNF)
superfamily such as Fas receptor (Apo1/CD95), death receptor 4/
TNF-Related apoptosis-Inducing ligand receptor 1 (DR4/
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receptor (LTbR), are capable of inducing apoptotic signals into
tumor cells following ligation with cognate death ligands from anti-
tumor immune cells [27–32]. However, tumor cells can develop
resistance to elimination by immune cells in a process termed
immunoediting [33]. Numerous studies have suggested that
inhibition of apoptotic death signaling pathways is a major
mechanism of escape from immune cell elimination, as both
cytolytic T-cells (CTL) and natural killer (NK) cells kill target cells
using these mechanisms. Interestingly, we have shown that
radiation can enhance or induce sensitivity to killing of tumor
cells by CTLs [34,35]. Our study explores the impact of sub-lethal
doses of ionizing radiation on multiple death receptor pathways
that could enhance productive interactions between cytolytic
immune cells and tumor cells.
TNF-related apoptosis-inducing ligand (TRAIL) is expressed on
numerous immune effector cells, including anti-tumor CTLs and
NK cells [28]. Ligation of TRAIL with DR4 or DR5 on tumor
cells induces the extrinsic apoptotic signal pathway, resulting in
death of target cells. Several investigators have pursued soluble
recombinant TRAIL, or agonistic antibodies to TRAIL-R, as
anticancer therapeutics [36–38]; though, many tumor cells exhibit
resistance to TRAIL killing [39–42]. Recent investigations have
sought ways to overcome this TRAIL-resistant phenotype using a
variety of therapeutic agents [41,43–45]. Although TRAIL and
Fas induce apoptosis by highly similar mechanisms, Fas agonists
have not been pursued as aggressively as TRAIL agonists due to
early observations of acute/lethal toxicity [46]. Utilization of these
pathways by anti-tumor effector CTLs or NK cells is an attractive
alternative to the administration of soluble agonists. This approach
also offers the potential for long-lasting circulation of effector/
memory CTLs in comparison to systemic drugs.
Colorectal tumor cells develop resistance to apoptosis signaling
through Fas [47,48], and Fas sensitivity decreases as tumor cells
progress to advanced stage and metastatic disease phenotypes
[49]. We and others have shown that radiation can modulate
expression of death receptors in tumor cells, and it has been
suggested that up-regulation of Fas following irradiation plays a
significant role in enhanced killing of diverse tumor cells by CTL
[50–53]. An in vivo murine radiation-immunotherapy study
reported that implanted tumors expressing dominant negative
Fas were not killed following irradiation, while functional Fas
expressing tumors were killed [50]. This mechanistic observation
has not borne out, however, in in vitro studies utilizing human
carcinomas [34,35,54]. No correlation was found between
increased levels of surface Fas expression and enhanced killing
by antigen specific CTLs following irradiation [34]. In fact, results
demonstrate that colorectal cells expressing surface Fas that is non-
functional (SW620), still exhibit enhanced lysis by CTL following
irradiation, indicating that enhanced susceptibility is not exclu-
sively Fas-dependent. Radiation has also been reported to increase
expression of TRAIL receptors on a variety of tumor cell types
[44,55–58]. Furthermore, IR has been shown to modulate
sensitivity to TRAIL-induced apoptosis [59]. Thus, radiation has
the potential to enhance apoptotic responsiveness through
alternate pathways.
In this study, we explore the hypothesis that colorectal
carcinoma cells can be modulated to become more sensitive to
killing through death receptors utilized by cytotoxic immune cells,
following exposure to sub-lethal irradiation. For these studies we
sought to further characterize the impact of sub-lethal doses of
radiation on death receptor (DR) expression, and to explore the
functional impact of radiation on cell death induced through these
pathways. We also sought to further explore the impact of
radiation across multiple doses as there are limited studies,
restricted to a single dose of radiation, specifically evaluating
colorectal cells. This will help drive the design of combination
radiation immunotherapy strategies. Specifically, we examined: a)
the effects of ionizing radiation, at sublethal doses, on the potential
modulation of DR expression, b) the functional consequences of
radiation on DR killing, c) the longevity of radiation induced
changes, and d) the role of intracellular sensitizers, such as bcl-XL
and c-FLIP (an integral element of apoptotic cell death pathways),
in the potential regulation of colon carcinoma apoptotic outcome
in combination treated cells.
To our knowledge, this is the first study to: a) simultaneously
evaluate the effect of tumor cell irradiation on multiple common
death receptors (Fas, TRAILR, LTbR and TNFR1), as well as the
intracellular sensitizers to death in numerous colorectal carcinoma
cells lines in a single study, b) evaluate multiple sub-lethal doses,
and c) evaluate the longevity or sustainability of these changes.
Results
Sub-lethally irradiated colorectal tumor cells continue to
proliferate
As tumor cells are known to become radio-resistant, we wanted
to separate the death inducing activity of radiation from it’s ability
to functionally and phenotypically alter tumor cells. To investigate
the influence of sub-lethal doses of ionizing radiation on colorectal
tumor cells we utilized 2.5, 5, and 10 Gy of ionizing radiation. A
minimal increase in dead cells was observed. Treatment of SW620
cells with 10 Gy of radiation resulted in 8.65% of dead cells, as
measured by 7AAD staining (Fig. 1), compared with non-
irradiated cells that contained 5.48% dead cells. The maximum
amount of cell death observed among the cell lines was 12% in
HCT116 cells irradiated with 10 Gy, compared to 7% cell death
in cells receiving 0 Gy. These cells were the most sensitive to
radiation. WiDr cells displayed the least amount of variation in cell
death as non irradiated (0 Gy), 2.5 Gy and 5 Gy samples
contained 8% dead cells, and WiDr cells irradiated with 10 Gy
contained 9% dead cells. All other cell lines at all other doses
resulted in less than 10% dead cells. This was repeated several
Figure 1. Tumor cells remain viable after 2.5, 5 and 10 Gy of
radiation. A. SW620 (squares), WiDr (circles) and HCT116 (triangles)
cells were irradiated with 2.5, 5 or 10 Gy of ionizing radiation. Irradiation
and non-irradiated cells (0 Gy) were cultured for 72 h. Adherent cells
were subsequently harvested and cell death was analyzed by 7AAD
staining and flow cytometric analysis. Experiment was repeated 3 times
with similar results.
doi:10.1371/journal.pone.0031762.g001
Synergy of Tumor Irradiation & Death Receptors
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31762times with no significant increase in cell death observed among the
irradiated colorectal tumor cells. Furthermore, there was no
decrease in viability as measured by trypan blue uptake on
irradiated SW620, HCT116, and WiDr cells (data not shown), nor
was there an increase in early apoptotic cells as measured by
Annexin-V staining (data not shown). Thus, the levels of
irradiation utilized in these experiments were considered to be
sub-lethal in these cell lines.
The impact of radiation on tumor cells is a balance between cell
death and cell proliferation. Therefore, we investigated the impact
of these sub-lethal doses of radiation on tumor cell proliferation by
measuring BRDU incorporation. 2.5 Gy of irradiation did not
significantly decrease proliferation of any of the three cell lines
used in this study (Fig. 2). Proliferation of SW620 and WiDr cells
was also not reduced following 5 or 10 Gy of radiation (Fig. 2A &
2B). Proliferation could, however, be significantly reduced by
administration of 30 Gy of radiation to both SW620 and WiDr
cells. In contrast, proliferation of HCT116 cells was impacted
significantly by radiation both at 5 Gy and 10 Gy (Fig. 2C).
Proliferation was reduced by 30% at 5 Gy and reduced by 60%
following 10 Gy. Importantly proliferation of HCT116 was not
completely eliminated (Fig. 2C), especially when compared to
25 Gy of radiation. Together these data indicate that viable and
proliferating cells remain after exposure to the doses of radiation
used in our studies.
Sub-lethal irradiation of colorectal tumor cells can
enhance sensitivity to killing through Fas receptor that is
sustained
Fas ligand (FasL) expressing CTL and NK cells can kill tumor
cells expressing the Fas receptor [28]. Radiation has been shown
to increase surface expression of Fas, however, numerous
colorectal cell lines, including HCT116 [27] and SW620 cells
[49], have been reported to be resistant to killing through Fas.
Moreover, they have also been shown to be resistant to radiation-
mediated apoptosis at 2–6 Gy of radiation. Interestingly,
simultaneous administration of 10 Gy of radiation and a novel
Fas crosslinking antibody, APO010, to HCT116 has recently
been reported to result in enhanced DNA fragmentation [60].
Differences reported on the sensitivity of HCT116 cells to Fas
signaling appear to be due to differences in cell sensitivity to anti-
Fas mAb vs FasL recombinant protein. We wanted to explore the
impact of combining these two treatments on apoptosis induced
through the Fas receptor in numerous colorectal cell lines. We
also wanted to further explore the impact of radiation dose. To
this end, we treated SW620, HCT116, and WiDr cells with 2.5,
5, and 10 Gy of irradiation. We initiated Fas-mediated death
72 h post-irradiation using the anti-Fas crosslinking antibody
CH11. Fas-mediated apoptosis was measured by active caspase-3
detection. SW620 cells have been reported to be resistant to
killing through Fas [49], and radiation did not change
susceptibility to Fas death in SW620 cells (Fig. 3A). In contrast,
treatment of both HCT116 cells and WiDr cells with radiation
resulted in enhanced Fas-mediated apoptosis (Fig. 3B & 3C).
This was detected when death was induced using both high
(1 mg/ml) and low (0.1 mg/ml) concentrations of CH11 antibody.
Enhanced cell death correlated well with increasing doses of
radiation. In the absence of CH11 antibody, active caspase-3
levels were less than 5% in all cell lines, confirming that the doses
of radiation used here can be considered sub-lethal in these cells
(data not shown).
The radiation-induced enhanced susceptibility to Fas did not
seem to be dependent on the magnitude of change observed in
surface levels of Fas detected by flow cytometry. 10 Gy of
radiation increased Fas expression to 60% in SW620 (Fig. 3D),
which had no susceptibility to Fas-induced death at any of the
doses of radiation. We found that 83% of HCT116 cells expressed
Fas upon 10 Gy radiation, as compared to 47% of WiDr cells
receiving the same dose (Fig. 3D). While HCT116 cells
demonstrated the largest increase in Fas expression post-
irradiation, WiDr cells demonstrated the largest increase on Fas-
induced apoptosis, reaching 50% apoptotic cells upon treatment
with 1 mg/ml of CH11 (compared to approximately 40%
apoptotic cells observed in HCT116). Therefore increased surface
expression of Fas could not be used as the predictor for sensitivity
to Fas-mediated cell death.
Both WiDr and HCT116 cells exhibited enhanced susceptibility
to Fas-induced cell death 72 h after exposure to radiation. It is
unclear how long radiation is able to sensitize tumor cells to killing
through Fas, and we next evaluated if this increased sensitivity to
Figure 2. Tumor cells continue to proliferate following sub-
lethal doses of radiation. Proliferation was measured 72 h after
r e c e i v i n g0 ,2 . 5 ,5 ,o r1 0 G yo fr a d i a t i o nb ym e a s u r i n gB R D U
incorporation. Cells receiving 25 or 30 Gy of irradiation were used as
a positive control for inhibition of proliferation. A. Proliferation of
SW620 cells. B. Proliferation of WiDr cells. C. Proliferation of HCT116
cells. Samples were done in triplicate at each dose. Experiment was
repeated 3 times with similar results.
doi:10.1371/journal.pone.0031762.g002
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irradiation. To evaluate this possibility, we sub-lethally irradiated
cells and waited five days before triggering death through the Fas
receptor. Interestingly, both cell types remained more sensitive to
Fas-induced killing if exposed to radiation first (Fig. 4B & 4C).
Both WiDr cells and HCT116 cells show nearly a 10% reduction
in the level of apoptotic cells as was observed at the earlier time
post-irradiation using 1 mg/ml of antibody. Importantly, both cell
lines remained sensitive even when the lower dose of CH11
antibody was used. Surprisingly, SW620 cells demonstrated some
sensitivity to killing through the Fas receptor at day five that was
not observed 3 days post irradiation (Fig. 4A). Approximately
20% of SW620 cells contained active caspase-3 following the
combination of 10 Gy and 1 mg/ml of CH11 and this result was
observed each time the experiment was conducted. These data
suggest that low doses of radiation can sensitize colorectal tumor
cells to killing through the Fas receptor that would not be sensitive
without radiation pre-treatment and that this effect lasts as long as
5 days post-IR.
Radiation increases expression of TRAIL receptors, but
not of TNFR1 or LTbR, in colorectal tumor cells
Numerous members of the TNF family of receptors are capable
of inducing death of tumor cells. We next wanted to evaluate if
sub-lethal doses of radiation were capable of modulating
expression of other death receptors. Lymphotoxin-a (LTa) and
LTb can be expressed by T-cells and function as a mediator of
tumor cell death through the LTbR [61,62]. Tumor cell death can
also be induced by ligation of this receptor by CD258/LIGHT (for
homologous to lymphotoxins, exhibits inducible expression, and
competes with HSV glycoprotein D for HVEM, a receptor
expressed by T lymphocytes) [63]. There are no reports on the
impact of radiation on tumor cell expressed LTbR. We examined
surface expression of LTbR on SW620, WiDr, and HCT116 cells
three days post-irradiation (Fig. 5A). In contrast to the up-
regulation observed in expression of Fas receptor, we observed no
change in the percent of cells expressing LTbR 72 h post-
irradiation with 2.5, 5 or 10 Gy. In fact, each of the cell lines
evaluated expressed LTbR on greater than 95% of the cells. We
also did not observe an increase in the amount of this receptor on
the cell surface as determined by mean fluorescence intensity (data
not shown). Interestingly, our data reveal that all of the colorectal
tumor cells examined in these studies express high levels of this
receptor.
Kimura (2000) et al. demonstrated enhanced activation of
apoptotic effector molecules following irradiation and treatment of
prostate cancer cells with TNF-a [64]and modulation of TNF-R1
has been observed in breast cancer cells following IR [56]. In
Figure 3. Functional enhancement of Fas receptor pathway in sub-lethally irradiated colorectal tumor cells. Human tumor cells were
mock-irradiated (0 Gy) or irradiated with 2.5, 5 or 10 Gy and re -cultured for 72 h (3-days). Cells were harvested and incubated with the indicated
concentrations of Fas crosslinking antibody CH11 or IgM isotype control antibody for 3 h. A. Non-functional Fas receptor signaling in SW620 cells
72 h post-IR. B. Functional Fas receptor signaling in WiDr cells 72 h post-IR. C. Functional Fas receptor signaling in HCT116 cells 72 h post-IR.
Experiment was repeated 3 times with similar results. D. Surface Fas levels, as determined by flow cytometry of stained cells 72 h post-IR.
doi:10.1371/journal.pone.0031762.g003
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change in surface expression of TNF-R1 72 h post-irradiation with
2.5 or 5 Gy (Fig. 5B). We did observed a small reduction in
expression following 10 Gy IR in all three cell lines. We also
evaluated cells one day and four days post-irradiation and
observed similar changes (data not shown).
Figure 5. Radiation can modulate surface expression of some but not all TNF family death receptors in colorectal tumor cell lines.
SW620, WiDr and HCT116 cells received 0 (black bar), 2.5 (dark grey bar), 5 (light gray bar) and 10 Gy (white bar) of radiation. Cells were re-cultured
for 72 h and then analyzed by flow cytometry for surface (A) LTbR, (B) TNF-R1, (C) DR4, and (D) DR5 surface expression (inset; MFI of DR5 expression is
shown for SW620 and HCT116 cells). Percent of cells expressing each death receptor is graphed. Cells stained with a fluorescently-labeled isotype
control antibodies were negative (not shown). Staining was repeated 3 times with similar results.
doi:10.1371/journal.pone.0031762.g005
Figure 4. Functional enhancement of Fas receptor pathway in sub-lethally irradiated colorectal tumor cells is sustained. Human
tumor cells were mock-irradiated (0 Gy) or irradiated with 2.5, 5 or 10 Gy and re -cultured for 120 h (5-days). Cells were harvested and incubated with
the indicated concentrations of Fas crosslinking antibody CH11 or IgM isotype control antibody for 3 h. A. Functional Fas receptor signaling in SW620
cells 120 h post-IR. B. Functional Fas receptor signaling in WiDr cells 120 h post-IR. C. Functional Fas receptor in HCT116 cells 120 h post-IR.
Experiment was repeated 3 times with same results.
doi:10.1371/journal.pone.0031762.g004
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TRAIL receptors in prostate [44,64], breast [56], and gastric
cancer [57,58] cells. Lastly, we wanted to evaluate the surface
expression of the TRAIL receptors DR4/TRAILR1 and DR5/
TRAILR2 in our three colorectal cell lines following exposure to
sub-lethal doses of radiation. Surface expression of DR4 was less
than 10% in all three cell lines prior to irradiation (Fig. 5C).
Three days after irradiation, each of the three cell lines
demonstrated increased surface expression in a dose dependent
manner. HCT116 cell showed the largest increase (,5% in 0 Gy
versus .35% in 10 Gy treated cells). A different pattern of
expression was observed for DR5 expression. WiDr cells were the
only cell line that expressed low levels of DR5 (15%) on the cell
surface before irradiation (0 Gy) (Fig. 5D). A dose-dependent
increase in surface DR5 expression was observed in these cells
72 h after radiation. In contrast, both SW620 and HCT116 cells
expressed high levels (.95%) of DR5 in the absence of radiation.
However, radiation did induce an increase in the density of DR5
on the surface of these cells in a dose-dependent manner as
measured by mean fluorescence intensity (Fig. 5D; inset MFI
numbers). Overall, these data reveal that sub-lethal doses of IR
induce increased expression of some death receptors (Fas, DR4
and DR5) but not all TNF related death receptors (LTbR and
TNF-R1) in colorectal tumor cells.
To determine how early radiation induced such changes and
how long they may last, we evaluated expression of DR4 at two,
four, and seven days post-irradiation. Radiation-induced up-
regulation was detectable as early as 48 h (Fig. 6A–6C) and
remained detectable as long as four (Fig. 6D–5F) and seven days
(Fig. 6G–6I) after radiation of HCT116 cells. Furthermore,
increased expression of DR4 was still detectable in both SW620
and WiDr cells seven days post-irradiation (data not shown).
Similarly, increase expression of DR5 also remained detectable
seven days after radiation (data not shown).
Sub-lethal irradiation of colorectal tumor cells can
enhance sensitivity to killing through TRAIL receptors
that is sustained
Radiation has previously been reported to very mildly modulate
sensitivity to TRAIL-induced apoptosis [59] in one of two
colorectal tumor cells lines (HCT116 cells and Colo205 cells).
However, these studies utilized independent agonists for DR4
(mapatumumab) and DR5 (lexatumumab) in combination with
5 Gy of radiation. There was a very small enhancement in
apoptosis through DR5 when used in combination with 5 Gy
radiation in HCT116 cells (25% dead cells with DR5 agonist alone
versus 40% dead cells with IR+lexatumumab), and no enhance-
ment in killing through DR4. For these studies, irradiation was
administered immediately before administration of antibodies and
apoptosis was detected 36 h after treatment. Similar studies have
evaluated co-treatment strategies on other tumor cells derived
from solid cancers. We wanted to more specifically investigate pre-
treatment with irradiation on subsequent killing of colorectal
tumor cells through death receptors. In addition, we sought to
evaluate whether radiation could enhance killing through TRAIL
receptors, several days later, using the soluble recombinant protein
capable of stimulating apoptosis through both DR4 and DR5.
SW620, HCT116, and WiDr cells were treated with 2.5, 5, and
10 Gy of irradiation. TRAIL receptor-mediated death was
initiated using recombinant TRAIL protein 72 h post-irradiation
and receptor-mediated apoptosis was measured by active caspase-
3 detection. We observed increased susceptibility to apoptosis
induction by TRAIL signaling in each of the three cell lines
evaluated in this study (Fig. 7A–C). Interestingly, SW620 cells,
which were not rendered sensitive to Fas killing by radiation, were
more sensitive to cell death via TRAIL following all doses of
radiation (Fig. 7A). This was observed even with radiation doses
as low as 2.5 Gy. Cell death was of higher magnitude when
100 ng/ml of TRAIL were used, as compared to the lower dose of
25 ng/ml (data not shown). A similar enhancement in TRAIL
mediated apoptosis was also observed with WiDr cells (Fig. 7B)
and HCT116 cells (Fig. 7C). HCT116 cells were sensitive to
TRAIL-mediated apoptosis both with and without irradiation
when 100 ng/ml of protein were used, and no increase in
apoptosis was observed (data not shown). However, the impact of
irradiation was observable using the lower dose of recombinant
protein (25 ng/ml) (Fig. 7C). Irradiation of HCT116 cells with
5 Gy IR followed by TRAIL receptor activation three days later
demonstrated almost twice as much apoptosis (.40%) when
compared to non-irradiated cells (23%) (Fig. 7C). Overall,
radiation enhanced TRAIL related death signaling in 3 of 3
colorectal tumor cell lines evaluated here.
We next wanted to investigate the longevity of this enhanced
apoptosis observed through TRAIL by sub-lethal irradiation of
tumor cells. We evaluated the sensitivity of irradiated cells to
TRAIL receptor-mediated apoptosis five days after irradiation.
Two of three lines (WiDr and SW620 cells) retained sensitivity to
TRAIL following 10 Gy of radiation (Fig. 7D–F). The degree of
sensitivity to TRAIL was reduced five days after radiation
(Fig. 7D& 7E), though it was not completely abrogated and
was still detectable. In contrast, HCT116 cells, which were already
very sensitive to TRAIL-induced cell death, lost some radiation-
enhanced sensitivity to TRAIL 5-days post irradiation as
compared to the sensitivity 3-days post irradiation (Fig. 7C &
7F). Overall, these data suggest that sub-lethal doses of radiation
can sensitize colorectal tumor cells to killing through the TRAIL
receptors that would not be sensitive without radiation pre-
treatment and that this effect can last as long as 5 days post-IR in
some tumor cells.
Sub-lethal irradiation of colorectal tumor cells does not
enhance sensitivity to killing through LTb receptors
Blocking LTbR with LTbR-specific neutralizing monoclonal
antibody has been reported to decrease CTL cytotoxicity against
tumor cells in vitro [32]. Furthermore, silencing LTbR using
specific short hairpin RNA was reported to reduce the ability of
perforin-deficient CTLs to induce tumor rejection in vivo. Each of
the three cell lines evaluated in this study expressed higher levels of
surface LTbR than Fas or TRAIL receptors. The agonistic anti-
LTbR mAb, 31G4D8, has been reported to induce cell death in
tumor cells in conjunction with IFN-c [65]. As expected, HT-29
cells demonstrated enhanced LTbR-induced cell death upon
treatment with IFN-c as measured by 7AAD uptake by flow
cytometry (Fig. 8A). No cell death was observed in cells treated
with 10 mg/ml of 31G4D8 in the absence of IFN-c, while death
was detected in 20% of HT-29 cells upon IFN-c treatment.
Slightly less death (17%) was detected in cells treated with 1 mg/ml
of 31G4D8. Not surprisingly, we observed no tumor cell death in
SW620, HCT116, or WiDr cells following treatment with the
LTbR mAb alone (Fig. 8B–D). To evaluate if radiation could
sensitize cells to killing through this pathway, SW620, HCT116,
and WiDr cells were treated with 5 and 10 Gy of irradiation. 72 h
post-irradiation, LTbR-mediated death was initiated using anti-
LTbR mAb. Under these conditions, tumor cell irradiation was
not able to increase the susceptibility to cell death induced by
LTbR signaling, and cell death remained below 3% in all cell lines
(Fig. 8B–D). LTbR-mediated apoptosis was also measured by
active caspase-3 detection as signaling through LTbR has been
Synergy of Tumor Irradiation & Death Receptors
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cell death [65]. We were unable to detect any active caspase-3
following LTbR activation in any of the cell lines evaluated,
including the HT-29 cells treated with IFN-c (data not shown).
Radiation of colorectal tumor cells modulates
intracellular sensitizers to apoptosis that do not correlate
with radiation-enhanced susceptibility to Fas or TRAIL
receptor death
We detected increased production of active caspase-3 following
Fas and TRAIL induced cell-death in irradiated tumor cells. To
confirm that cells with increased detection of active caspase-3 were
truly undergoing apoptosis, we evaluated cells for surface
expression of phosphatidylserine (PS) as an indicator of early
apoptotic cells. Figure 9 shows the number of early apoptotic cells
(annexin-V
+/7AAD
2) in WiDr cells treated 72 h post-IR with the
agonistic Fas antibody (CH11). 2.19% of non-irradiated cells are
undergoing apoptosis upon Fas signal induction as compared to
15.7% and 36.4% in cells irradiated with 5 and 10 Gy respectively
(Fig. 9A–C). Irradiated cells treated with an isotype control
antibody contain less than 3% apoptotic cells regardless of whether
they were irradiated or not. Importantly less than 6% of cells in all
treatment groups were in late apoptosis or necrosis as defined by
annexin-V
+/7AAD
+ in this short 5 h assay. SW620 cells also
demonstrated increased apoptosis following Fas receptor triggering
Figure 6. Radiation-induced increase in DR4 expression is sustained for up to a week. HCT116 cells were irradiated with 0, 5 or 10 Gy
irradiation. Cells were re-cultured, harvested and subsequently stained for surface DR4 after 2 days (A–C), 4 days (D–F), and 7 days (G–I). Each
experiment was repeated twice with similar results. Cells stained with a PE-labeled isotype control antibody were below 5% (not shown).
doi:10.1371/journal.pone.0031762.g006
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detected in irradiated tumor cells undergoing TRAIL-induced
death (Fig. 9H). Thus, death induced by IR pre-treatment
followed by death receptor ligation is apoptotic.
There are numerous well-characterized intracellular sensitizers
to apoptotic death signals induced through death receptors.
Molecules, such as Bcl-2, Bcl-XL, survivin, and c-FLIP are known
to inhibit apoptosis [66,67]. Bcl-XL acts on the mitochondria of a
cell by inhibiting the release of cytochrome c, which is needed to
initiate apoptosis [39]. SW620 cells displayed marked decreased
expression of Bcl-XL upon 10 Gy radiation, as determined by
immunoblotting (Fig. 10A). WiDr cells displayed mild reduction
in Bcl-XL protein at 10 Gy dose (Fig. 10B). In contrast, there was
low to no reduction in Bcl-XL expression in HCT116 cells
(Fig. 10C). Surprisingly, SW620 cells had an increase in Bcl-XL
expression at low doses of IR (2.5 Gy) that was reproducibly
observed in our experiments. b-actin was used as protein loading
control for these experiments. cFLIP inhibits activation of caspase-
8 needed for the execution of apoptosis [68,69]. HCT116 cells
were the only cells to respond to radiation by reproducibly
decreasing expression of cFLIP following 10 Gy (Fig. 10C). No
reduction in cFLIP protein was ever observed in either SW620 or
WiDr cells (Fig. 10A & 10B). Thus IR was able to reduce
expression of some anti-apoptotic proteins in colorectal tumor
cells.
We next wanted to see if the enhanced functional killing
through either Fas or TRAIL would correlate with the changes in
anti-apoptotic proteins. Sensitivity to Fas and TRAIL induced
apoptosis were compared with changes in expression of c-FLIP
and Bcl-XL. SW620 displayed the greatest reduction in Bcl-XL
protein levels 72 h post-IR; however, SW620 cells are not
rendered susceptible to Fas-induced apoptosis (Fig. 10D), while
WiDr and HCT116 are very susceptible (Fig. 10E & F). There is
no loss of cFLIP protein expression in either SW620 or WiDr cells,
though Fas signaling results in apoptosis in WiDr cells (Fig. 10E),
but not in SW620 cells. Indeed, WiDr cells are sensitive to both
Fas and TRAIL killing and there is no major reduction in either
Bcl-XL or cFLIP. Most obviously, SW620 is sensitive to TRAIL
killing, even at the dose of radiation that appears to increase
expression of Bcl-XL (2.5). Both WiDr and HCT116 cells are very
Figure 7. Functional enhancement of TRAIL receptor pathway in sub-lethally irradiated colorectal tumor cells is sustained. Human
tumor cells were mock-irradiated (0 Gy) or irradiated with 2.5, 5 or 10 Gy and re-cultured for the indicated times. Cells were harvested and incubated
with the indicated concentrations of recombinant TRAIL protein or media for 3 h. Functional TRAIL receptor signaling in (A) SW620, (B) WiDr and (C)
HCT116 cells 72 h post-IR (3-days). SW620 and WiDr cells were incubated with 100 ng/mL of recombinant protein and HCT116 cells were incubated
with 25 ng/mL of protein. Experiments were repeated 3 times with similar results. Functional TRAIL receptor signaling in (D) SW620, (E) WiDr, and (F)
HCT116 cells 120 h (5-days) post-IR. Experiments were repeated 2 times with similar results.
doi:10.1371/journal.pone.0031762.g007
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HCT116 exhibit a mild reduction in cFLIP protein expression at
10 Gy (and express the lowest overall levels), while WiDr cells
show no change in cFLIP expression. Thus in our studies,
radiation-induced changes in apoptotic inhibitors do not correlate
with enhanced killing through Fas or TRAIL death receptors.
Enhanced susceptibility to death receptor signaling could also
be the result of increased expression of necessary pro-apoptotic
proteins. In some cell lines, death-receptor mediated activation of
caspase-8 is known to simultaneously activate the mitochondrial
pathway through production of Bid [70]. Increased expression of
Bid has been reported to increase death receptor apoptosis [71].
We observed no increased expression of active Bid protein
expression in the cells evaluated in this study at any of the doses
of radiation evaluated (Fig. 10G–H). Bax, another pro-apoptotic
protein, promotes death receptor mediated apoptosis via the
mitochondria, and deletion of Bax has been reported to promote
resistance to DR4/DR5 killing [72,73]. No change in Bax
expression was observed in WiDr or HCT116 cells following IR
(Fig. 10G–H). In fact, we actually observed slightly reduced levels
of Bax protein in SW620 cells treated with 10 Gy, although, these
cells were still very susceptible to cell death through TRAIL. Puma
is a p53-induced pro-apoptotic protein that promotes death by
binding to pro-survival Bcl-2 family members and interfering with
their interactions with pro-apoptotic Bak and Bax [74]. We
observed mildly decreased expression of Puma in SW620 cells
treated with 10 Gy and no change in expression in WiDr cells or
HCT116 cells (Fig. 10 G–H). Thus enhanced death receptor
signaling does not appear to be due to increased expression of pro-
apoptotic proteins.
Discussion
Colorectal tumor cells develop resistance to many apoptotic
pathways, including Fas [47] and TRAIL [39–41]. Apoptosis
decreases as tumor cells progress to advanced stage and metastatic
disease phenotypes [49]. The aim of this study was to both
characterize the expression of death receptors in colorectal cancer
cells, and to seek to manipulate these levels with irradiation.
Moreover, we wanted to evaluate the longevity of these changes.
For these studies we used doses of radiation considered to be sub-
lethal to separate out the direct cytotoxic effects of radiation from
its ability to phenotypically modulate tumor cells (Fig. 1). Data
from our study suggests that tumor cells that are not killed by
radiation are still susceptible to death receptor initiated cell death.
Cells receiving up to 10 Gy of irradiation continue to proliferate
(Fig. 2), and this finding could be particularly relevant for
radioresistant tumor cells. These data suggest that administration
of radiation may still be relevant even in situations where tumor
cells are not dying as a direct consequence of radiation. In
addition, radiation can kill both malignant cells and non-
malignant cells and can have significant dose-limiting toxicities,
thereby making the use of lower radiation doses useful.
A murine in vivo model demonstrated elimination of tumor
burden in CEA positive tumor cells in a CEA-Tg use model, using
the combination of sub-lethal tumor cell irradiation and pox viral
CEA expressing viral vectors [50]. This model showed that anti-
tumor activity was dependent on Fas, as Fas expression was
upregulated and anti-tumor activity was abrogated if cells
expressing dominant-negative Fas were implanted instead. In
contrast, experiments evaluating human tumor cell lines in vitro
showed enhanced killing of irradiated tumor cells by CEA specific
human CTLs that could not be correlated with surface Fas
expression [34]. Furthermore, this enhanced killing by CTLs was
exhibited in cells where the Fas pathway is non-functional. Here
we show increased expression of surface Fas on three colorectal
cell lines at doses as low as 2.5 Gy (Fig. 3D). Though surface Fas
was increased in SW620 cells following radiation, these cells
remain refractory to cell death initiated through the Fas receptor
(Fig. 3A). These data suggest that expression of surface Fas
receptor following therapy cannot be used to predict sensitivity to
death through this receptor. This is further demonstrated by
observations that the tumor cell line with the smallest increase in
surface Fas (WiDr cells; Fig. 3D) had the most sensitivity to Fas-
induced cell death signals (Fig. 3B). These results highlight
important differences between observations made in murine
models and those observed using human tissues. The focus of
Figure 8. Cell death through the LTbR is not enhanced by sub-lethal irradiation of colorectal tumor cells. Cells were incubated on plates
coated with 10 mg/ml or 1 mg/ml of anti- LTbR mAb (31G4D8) for 48–72 h. Cell viability was determined by 7-AAD uptake comparing cells treated
with 31G4D8 versus cells cultured in medium alone and isotype control mAb. A. As a positive control HT-29 cells were incubated with 31G4D8 in
conjunction with 50 units/ml IFN-c (+IFN- c), or without (-IFN- c) as a negative control. B–D. Human tumor cells were mock-irradiated (0 Gy) or
irradiated with 5 or 10 Gy and re-cultured for 72 h. SW620 (B), Widr (C) and HCT116 (D) cells were then harvested and incubated on plates coated
with 10 mg/ml or 1 mg/ml of 31G4D8 for 48–72 h. Experiments were repeated 3 times with similar results.
doi:10.1371/journal.pone.0031762.g008
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irradiation of tumor cells, isolated ex vivo, from human tumor
samples.
We observed enhanced susceptibility to Fas death receptor
signals in both WiDr cells and HCT116 cells (Fig. 3B–C) 3-days
after sub-lethal tumor cell irradiation. This effect was observed
when doses as low as 2.5 Gy were utilized, and was present at both
high and low concentration of CH11 antibody. In contrast, Sheard
et al. [48] reported radiation-induced up-regulation of Fas
receptor expression that had little or no effect on responsiveness
to CH11 antibody in HCT116 cells. Yet in their studies, protein
synthesis was inhibited with cyclohexamide at the time of CH11
antibody administration. Thus it appears that enhanced suscep-
tibility to Fas signaling is dependent on protein synthesis and
Figure 9. Enhanced sensitivity to receptor-mediated cell death by sub-lethal irradiation is apoptotic. Kinetics of dead and apoptotic
cells were analyzed by annexin V–PE/7AAD staining of cells and flow cytometry. A–F. WiDr tumor cells were mock-irradiated (0 Gy) or irradiated with
5 or 10 Gy and re -cultured for 72 h. Cells were harvested and incubated with the indicated concentrations of Fas crosslinking antibody CH11 (A–C) or
IgM isotype control antibody (D–F) for 5 h. Percent of apoptotic cells are represented in the upper left quadrant as Annexin-V
+ and 7AAD
2.B .
Induction of apoptosis (Annexin-V
+ and 7AAD
2) following Fas receptor signaling in SW620 cells 120 h post-IR. Cells were treated with 1 mg/ml of
CH11 mAb for 5 h. C. Induction of apoptosis (Annexin-V
+ and 7AAD
2) following TRAIL receptor signaling in HCT116 cells 72 h post-IR. Cells were
incubated with 100 ng/ml of recombinant TRAIL protein for 5 h. Experiment was repeated 3 times with similar results.
doi:10.1371/journal.pone.0031762.g009
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tered the antibody 4 h after 8 Gy irradiation. SW620 cells are
resistant to Fas-induced cell death. Interestingly, we observed
sensitization to Fas-induced death in a long-term culture (5 days)
(Fig. 4A). These data suggesting that the timing of tumor cell
irradiation and initiation of death receptor signaling may be
important and clinicians may need to allow time for phenotypic
modulation of tumor cells to achieve the maximum amount of cell
death.
Targeting the TRAIL receptor is an attractive therapy for
cancer, and numerous studies suggest that this pathway can be
modulated by other therapies. Studies have shown increased
sensitivity to TRAIL following IFNc and TNFa treatment [41].
Others have reported that agents such as multikinase inhibitors,
histone deacetylase inhibitors, and ceramide can modulate this
signaling pathway [43,45,75]. These modalities, however, are not
utilized as commonly as radiation for the therapy of cancer [41].
Marini et al. [58] reported decreased expression of DR4 and
increased expression of DR5 in colorectal cells receiving 10 Gy of
radiation. Interestingly, DR5 expression was increased 18 h post-
irradiation but not at 24 h post-irradiation. These studies
evaluated both combined and sequential administration of
radiation and TRAIL. Similar to this report, we observed
increased expression of DR5 in our three cell lines (Fig. 5D).
Interestingly, we also observed increased expression in DR4 in
three of three colorectal cell lines examined (Fig. 5C), and no
decreased expression. Though Marini et al. evaluated different cell
lines than those evaluated here (Colo 205 and HCT-15), they did
report enhanced killing when combined with radiation. In another
study, radiation was reported to modulate sensitivity to TRAIL-
induced apoptosis [59] with 5 Gy in HCT116 cells. The
enhancement was low in this study, with 25% cell death with
DR5 agonist (lexatumumab) alone enhanced to 40% when
radiation was added. Notably, there was no enhancement when
the DR4 agonist (mapatumumab) was used in combination with
radiation in these same cells. There was no enhancement in
TRAIL-induced apoptosis in combination with radiation in the
other colorectal cell line (Colo 205) evaluated in the same study.
Irradiation was performed immediately before administrating the
antibodies, and it is likely that changes in gene expression are
necessary to achieve maximum synergy between these two
modalities. Here we report enhanced TRAIL receptor induced
death following radiation in three of three colorectal cell lines
(Fig. 7), including SW620 cells that are generally considered
Figure 10. Changes in the expression of anti-apoptotic molecules following tumor cell irradiation. A–C. Expression of Bcl-XL and c-FLIP
was detected by western blot 72 h post-irradiation in SW620, WiDr, and HCT116 cells. b-actin was used as a loading control. D–E. Comparison of
susceptibility to Fas (1 mg/mL) and TRAIL (100 ng/ml) death receptor induced apoptosis. Susceptibility to apoptosis is represented as: (0) denotes no
apoptosis as ,3%, (+) denotes 3–10%; (++) denotes 11–20%, (+++) denotes 21–30%, and (++++) denotes greater than 31% of cells positive for active
caspase-3 in the functional death receptor assays. G–H. Expression of pro-apoptotic proteins Bid, Puma and Bax was detected by western blot 72 h
post-irradiation in SW620, WiDr and HCT116 cells. b-actin was used as a loading control. Membranes were probed simultaneously and exposed to film
for the same amount of time.
doi:10.1371/journal.pone.0031762.g010
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enhanced sensitivity to TRAIL-induced cell death was observable
as long as 5 days post irradiation in these cells. In contrast,
HCT116 cells, which were the most sensitive to TRAIL-induced
cell death in the absence of radiation, lost some radiation-
enhanced sensitivity to TRAIL 5-days post irradiation as
compared to the sensitivity 3-days post irradiation (Fig. 7C &
7F). This sensitivity does not appear to be a result of the loss of
radiation-induced changes in surface TRAIL receptors as changes
in surface TRAIL were detectable as long as seven days following
IR (Fig. 6). Overall, our data suggest that colorectal cells are more
susceptible to TRAIL-induced death signals post-irradiation and
that TRAIL receptor agonists, that signal both DR4 and DR5, are
preferable.
As noted above, TNF-a and IFN-c were reported to enhance
TRAIL-induced cell death of tumor cells [41] and here we have
shown that radiation can also enhance TRAIL-induced death, in
the absence of such cytokines. Similarly, IFN-c has been reported
to enhance LTbR-induced cell death in tumor cells treated with
the mAb (31G4D8) but was not essential for LTbR death induced
by a pentameric form of the antibody (CBE11) [31]. We wanted to
determine if tumor cell irradiation alone could enhance LTbR
mediated cell death signaling in a manner similar to that observed
with Fas and TRAIL killing, in the absence of exogenous
cytokines. Interestingly, though the tumor cells utilized for these
studies expressed high levels of surface LTbR( Fig. 5A), we were
unable to induce cell death through this receptor pathway.
Moreover, tumor cell irradiation did not sensitize cells to LTbR-
induced cell death (Fig. 8), as it did for Fas and TRAIL-induced
death. It remains to be determined, however, if irradiation could
further enhance cell death of tumor cells treated with anti-LTbR
mAb and IFN-c in combination and this is currently under
investigation. Additionally, it would be interesting to see if
radiation can enhance tumor cell death triggered by the
pentameric LTbR (which is not commercially available). Further-
more, while we observed increased expression of Fas, DR4, and
DR5 in this study, we did not detect an increase in the expression
of LTbR or TNF-R1 (Fig. 5A–B). These results indicate that
LTbR agonists or TNF-R1 agonists may not be best suited for use
in combination with radiation therapy. In fact, 10 Gy of radiation
appears to mildly reduce expression of TNF-R1 in colorectal cells
(Fig. 5B). However, further investigation is required to determine if
there are conditions under which radiation can have an impact on
the functional activity of these two pathways irrespective of
changes in surface expression.
Marini et al. did report enhanced killing of two colorectal tumor
cell lines at 12 and 48 h post-treatment. According to the authors
of that study, TRAIL was added either directly after cell
irradiation or 12 h later, to allow for receptor up-regulation. In
our studies we irradiated tumor cells and waited several days post-
irradiation before triggering the death receptors. Enhanced
responses to both Fas and TRAIL receptor signaling were
detected as long as five days after tumor cell irradiation (Fig. 4A–
C and Fig. 7D–F). Moreover, we observed up-regulation of DR4
as early as 48 h post-irradiation and as long as seven days post-
irradiation (Fig. 6). Overall, the results from Marini et al., in
combination with the results of this current report provide
evidence that the treatment window to benefit from radiation
enhanced death receptor signaling can be as early as 12 h and as
late as one week after radiation.
We showed that receptor-mediated apoptosis was enhanced by
tumor cell irradiation (Fig. 9). Immune effector cells utilize these
apoptotic pathways as a part of the death receptor killing
mechanism. Killing initiated through Fas and TRAIL receptors
are well-studied pathways that rely on induction of a cascade of
apoptotic proteins, including caspases and Bcl-2 protein family
members to execute death of a target tumor cell [28]. These
pathways are also important for traditional granzyme/peforin
mediated killing of tumor target cells. In particular, Bid is known
to promote the intrinsic apoptotic pathway to amplify cell death.
As such, cell death induced via death receptors can be modulated
or prevented by high expression of intracellular sensitizers to
apoptosis, such as Bcl-2, Bcl-XL, survivin, or cFLIP. Agents that
can decrease the expression of these molecules have been reported
to enhance death receptor mediated death. TNF-a and IFN-c
were shown to enhance TRAIL killing by decreasing bcl-xL
expression [41]. We have also previously shown that bcl-2 mRNA
expression was reduced following sub-lethal irradiation of tumor
cells [35]. Huerta et al. [49] showed that SW620 cells have
acquired genetic defects in apoptotic pathways, which may explain
the ability of advanced cancer cells to escape anti-tumor immune
cells. Here we show that bcl-2 family members cannot completely
explain enhancement of death receptor killing (Fig. 10). For
example, WiDr cells that were killed better by both Fas and
TRAIL receptor signaling post-IR had the highest overall
expression of Bcl-XL and c-FLIP protein levels. SW620 cells
displayed marked reduction in Bcl- XL protein levels 72 h
following 10 Gy IR; however, they were not sensitive to Fas-
induced cell death at this time in contrast to HCT116 cells with no
reduction that were very sensitive to Fas-induced cell death. Thus,
enhanced killing of sub-lethally irradiated tumor cells did not
correlate with changes in death receptor expression or other
intracellular sensitizers to death receptor mediated apoptosis, such
as c-FLIP or bcl-XL. We also found no correlation with changes in
the expression of pro-apoptotic proteins, such as Bid, Puma, or
Bax (Fig. 10G–I). We are currently exploring other pro-apoptotic
and anti-apoptotic proteins that could be responsible for the
observed differences in susceptibility. For example, White-
Gilbertson [40] suggests that sensitivity to TRAIL in SW620 cells
is regulated by ceramide production that modulates caspase-3
translocation to the nucleus.
Death receptor ligands, such as Fas-ligand and tumor necrosis
factor-related apoptosis inducing ligand (TRAIL) are potentially
useful for combination therapy of cancer. These death ligands can
be administered as external soluble agents or, alternatively, by
induction of antitumor CTL to attack target cells. It is important
to note that the Fas Ligand (FasL) on immune cells are trimerized
and commercially available recombinant FasL and Fas mAb
(CH11) may not mimic the physiological signal. Administration of
10 Gy of radiation and a novel trimerized FasL protein, APO010,
to HCT116 simultaneously resulted in enhanced DNA fragmen-
tation [60]. SW620 cells, which are generally considered resistant
to both FasL and TRAIL may be more susceptible to Fas signaling
induced by APO010. That said, in vivo 10 Gy+APO010 every
48 h (begun the same day as IR) did not enhance the efficacy of
radiation alone. This could be due to the insufficient circulating
amounts of this antibody, poor half-life, or inability of the antibody
to access modulated tumors. In contrast, induction of anti-tumor
CTLs or NK cells may be able to better suited to utilize this
pathway. Future investigations will evaluate combination RT
immunotherapy experiments evaluating human tumor cell lines in
an in vivo murine xenograft model.
Antitumor effector cells occur naturally in cancer patients and
can be generated or increased by numerous therapeutic
approaches [19,21,22]. We are interested in exploring basic
aspects of the death receptor pathways utilized by cytolytic
immune cells, which may have implications for designing
improved immunotherapeutic strategies. In this study we system-
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enhancement, of common receptors used to induce death in
tumor cells following sub-lethal tumor cell irradiation. Overall, we
found that sub-lethal irradiation of human colorectal tumor cells
imparts enhanced and sustained susceptibility to multiple death
signaling receptor pathways. Our results indicate that utilizing
modalities, such as ionizing radiation, which is commonly used in
the clinic, may promote more favorable immune cell activity
toward colorectal tumor cells. The mechanism by which radiation
sensitizes colorectal carcinoma cells to killing through Fas and




Colorectal tumor cell lines HCT116 and WiDr were generously
provided from the Laboratory of Tumor Immunology and
Biology, NCI, NIH [34]. Human colorectal carcinoma cell line
SW620 was generously provided by Zhi-Ren Liu [76] from
Georgia State University, Department of Biology. HT-29 cells
were originally purchased from ATCC. All cells were cultured in
media designated by ATCC for propagation and maintenance.
Cells were incubated at 37uC incubator with 5% CO2.
Tumor irradiation
Human tumor cells were harvested while in log-growth phase.
Tumor cells, in 10 ml suspension, were placed on ice and
irradiated (0–15 Gy) by
137Cs source (Gammacell-1000; AECL/
Nordion. Kanata, Ontario, Canada) at a dose rate of 0.70 Gy/
min. Control samples were also placed on ice but not irradiated.
Both irradiated and non-irradiated cells were then washed in fresh
media and seeded in tissue culture flasks.
Tumor cell proliferation assay
Proliferation rates were determined by measuring the uptake of
5-bromo-20deoxyuridine (BRDU) in triplicate. Carcinoma cell
lines were treated with 0, 2.5, 5, or 10 Gy of radiation, and 1610
4
cells were plated in 50 ul and were allowed to adhere overnight in
10% media in a 96-well plate. After three days, plates were
harvested and assayed for BRDU incorporation 18 h before
harvest BRDU was added to the culture. Proliferation was
measured using the DELFIA cell proliferation kit, according to
manufacturer’s instructions, and luminescence was detected using
a Victor 3 plate reader (Perkin Elmer. Waltham, Massachusetts).
Flow cytometric analysis
Cell surface staining of tumor cells was performed using the
following primary labeled mAb - CD95-PE, LTbR-PE, DR4-PE,
DR-5-APC - and the appropriate isotype matched controls. Surface
expression of TNF-R1 (CD120a) was performed with a two-step
protocol using biotin labeled TNF-R1, followed by streptavidin-PE
secondary staining (BD Biosciences. San Diego, CA). 7AAD
staining was used as a measure of cell death, following manufac-
turer’s instructions. Antibodies were purchased from either BD
Biosciences (San Diego, CA) or BioLegend (San Diego, CA).
Stained cells were acquired on a BD Fortessa flow cytometer using
FACSDiva software (BD PharMingen. San Diego, CA). Isotype
control staining was less than 5% for all samples analyzed. Dead
cells were excluded from the analysis based on scatter profile.
Functional death receptor assay
Human tumor cells were non-irradiated (0 Gy) or irradiated
(2.5, 5, and 10 Gy) and re-cultured. After 72 h or 120 h, cells were
harvested and counted. Human tumor cells were incubated for 3 h
with varying concentrations of agonistic anti-Fas antibody, clone
CH11 (MBL. Watertown, MA) or recombinant TRAIL protein
(Millipore. Billerica, MA). Control cells were incubated with IgM
isotype control antibody (BD Biosciences. San Diego, CA). Jurkat
cells were used as a positive control for Fas-mediated cytotoxicity.
Cells were subsequently fixed and permeabilized before being
stained for intracellular active caspase-3 with a PE-labeled
monoclonal antibody (BD Biosciences. San Diego, CA). The level
of activated caspase-3 was quantified by flow cytometry, as
described above. Alternatively, for experiments to confirm
apoptotic cell death, cells were harvested and stained using
Annexin-V-PE and 7-actinomycin D (7-AAD) according to
manufacturers instructions (BD Biosciences. San Diego, CA).
Background staining observed with IgM isotype control antibody
(Fas functional assays) and cells incubated in media (for TRAIL
functional assays) was subtracted out.
For LTbR death assays, 72 hr post-IR cells were loaded in
culture plates pre-coated with 10 mg/mL or 1 mg/mL of agonistic
anti-LTbR monoclonal antibody (mAb) in conjunction with 50
units/ml IFN-c (for HT29 cells) or media (SW620, WiDr,
HCT116) and were incubated for 48–72 h. Cell viability was
determined using the DNA-specific viability dye 7-AAD compar-
ing treated cells versus cells cultured in medium alone and isotype
control mAb. Background staining observed with mouse IgG2b
isotype control antibody was subtracted out.
Western blotting
Antibodies used in this study were directed against the
following: c-FLIP (Cell Signaling #3210. Danvers, MA) at
1:1000, Bcl-XL (Cell Signaling #2764) at 1:1000, Bid (Cell
Signaling #2002. Danvers, MA) at 1:1000, Puma (Cell Signaling
#4976. Danvers, MA) at 1:1000, Bax (Cell Signaling #5023.
Danvers, MA) at 1:1000 and b-actin (Cell Signaling rabbit #4970,
mouse #3700. Danvers, MA). Human colorectal cancer cells were
treated with ionizing radiation at doses ranging from 0 Gy to
10 Gy. Cells were lysed 72 h post-irradiation using NP40 cell lysis
buffer. Protein concentration of lysates was determined by a BCA
Protein Assay (Thermo Scientific Pierce. Rockford, IL) and 7 mgo f
protein used in Western blot analysis. Samples for electrophoresis
were prepared with Laemmli sample buffer (BIO-RAD. Hercules,
CA), 5% b-mercaptoethanol, and were run on 12% SDS-PAGE
gels (BIO-RAD. Hercules, CA). Proteins were transferred onto
nitrocellulose membranes for 1 h at 100 V in a mini-Protean III
transfer tank (BIO-RAD. Hercules, CA), and blocked for 1 h at
room temperature in blocking buffer 16 TBS, 0.1% Tween-20
(TBS-T) with 5% w/v nonfat dry milk. Membranes were
incubated overnight at 4uC, with antibodies in primary antibody
dilution buffer containing 16TBS, 0.1% Tween-20 with 5% BSA.
Membranes were washed 36for 30 min in TBS-T, and incubated
with HRP-conjugated anti-rabbit antibody (GE Healthcare.
Piscataway, NJ) at room temperature for 1 h. Membranes were
subsequently washed with TBS-T and developed with Amersham
ECL Western blotting analysis system (GE Healthcare. Piscat-
away, NJ). Following detection of cFLIP and Bcl-XL proteins,
membranes were striped and re-probed for b-actin protein.
RNA isolation
Cells were irradiated and seeded in T-75 flasks at 0.5 to 1610
7
cells/flask. After 24 h, cells were harvested from flasks and total
RNA was extracted and purified using the RNeasy mini kit
(Qiagen Inc. Valencia, CA) according to the manufacturer’s
instructions. Purified RNA was DNase-treated by Rnase-free
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Quantitative real-time PCR
For selected cell lines, real-time PCR analysis was performed on
cDNA isolated from irradiated or non-irradiated cells. cDNA was
synthesized from 500 ng RNA isolated in a standard RT reaction.
Cell lines were subjected to radiation at doses between 0 Gy to
10 Gy and harvested 24, 48, and 72 h post-irradiation. RNA
samples were reverse transcribed to cDNA using random hexamer
primers (Finnzymes. Vantaa, Finland). Amplification of cDNA was
done using DyNaAmo SYBR Green (Finnzymes. Vantaa, Finland)
and the following sequences of primer sets: cFLIP (l) forward 59
CGG ACT ATA GAG TGC TGA TGG 39 and reverse 59 GAT
TAT CAG GCA GAT TCC TAG 39; cFLIP (s) forward 59 CGG
ACT ATA GAG TGC TGA TGG 39 and reverse 59 AGA TCA
GGA CAA TGG GCA TAG 39; GAPDH forward 59 TTC GTC
ATG GGT GTG AAC 39 and reverse 59 AGT GAG CTT CCC
GTT CAG C 39; Bcl-2 forward 59 GAG GAT TGT GGC CTT
CTT TG 39 and reverse 59 GCC GGT TCA GGT ACT CAG
TC 39; survivin forward 59 CCA GAT GAC GAC CCC ATA
GAG 39 and reverse 59 TTG TTG GTT TCC TTT GCA ATT
TT 39; HPRT forward 59 TGG ACA GGA CTG AAC GTC
TTG 39 and reverse 59 CCA GCA GGT CAG CAA AGA ATT
TA 39. Primers were synthesized by Integrated DNA technologies
(Coralville, IA). Cycling conditions were set as the following: (a)
2 min at 5uC (b) 15 min at 95uC (c) 30 cycles of: 15 s at 95uC, 30 s
at (57uC for bcl-2/GAPDH, 60uC for cFLIP/survivin/HPRT),
30 s at 72uC, followed by (d) 7 min at 72uC.
Statistical Analysis
Tests of significance are reported as p values, derived from
Student’s t-test, using a 2-tailed distribution and calculated at 95%
confidence. Statistical tests were carried out with the software
packages Graph-Pad InStat/Prism (GraphPad Software, Inc. San
Diego, CA).
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